Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 1.00 |
| ▸ | CCNE2 | O96020 | 14/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 14/20 | 1.00 |
| ▸ | CDK2 | P24941 | 14/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6035362 | 0.99 | GSK3B (0.98) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6034863 | 0.99 | GSK3B (0.98) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL3331549 | 0.91 | GSK3B (0.84) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL3327724 | 0.91 | GSK3B (1.00) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6034147 | 0.91 | GSK3B (0.83) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6035110 | 0.91 | GSK3B (0.98) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL3329346 | 0.89 | GSK3B (1.00) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| Hydrochloric Acid SCHEMBL6034625 | 0.88 | GSK3B (0.98) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL29733651 | 0.88 | GSK3B (1.00) | GSK3BCCNE2CCNE1CDK2GSK3A | |
| SCHEMBL3327702 | 0.88 | GSK3B (1.00) | GSK3BCCNE2CCNE1CDK2GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101394851-A | Gsk-3 inhibitors for the treatment of osteoporosis | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | CN | claimed |
| US-20070213322-A1 | Administering 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; glycogen synthase kinase-3-beta inhibitor; osteoporosis; osteogenesis; increased cancellous bone; increased bone mineral density; strenthening to reduce breakage;enhanced fracture healing | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | US | claimed |
| US-20100137330-A1 | Use | BHAT RATAN | 2010-06-03 | — | — | US | disclosed |
| US-7576093-B2 | Method of treatment of bone-related disorders or conditions | ASTRAZENECA AB (SE) | 2009-08-18 | — | — | US | disclosed |
| CN-101394851-A | Gsk-3 inhibitors for the treatment of osteoporosis | ASTRAZENECA AB (SE) | 2009-03-25 | — | — | CN | disclosed |
| US-20070213322-A1 | Administering 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; glycogen synthase kinase-3-beta inhibitor; osteoporosis; osteogenesis; increased cancellous bone; increased bone mineral density; strenthening to reduce breakage;enhanced fracture healing | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137330-A1 | Use | SLC9A3, SOST, PHF13 | GSK3B 1106/4885CCNE2 2890/4885CCNE1 3246/4885 |
| US-20070213322-A1 | Administering 3-amino-6-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]-N-pyridin-3-ylpyrazine-2-carboxamide; glycogen synthase kinase-3-beta inhibitor; osteoporosis; osteogenesis; increased cancellous bone; increased bone mineral density; strenthening to reduce breakage;enhanced fracture healing | GSK3B, GSK3A, STK3 | GSK3B 1/4885CCNE2 3350/4885CCNE1 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.